NASDAQ:FCSC - Fibrocell Science Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $2.24 -0.02 (-0.88 %) (As of 04/19/2019 04:00 PM ET)Previous Close$2.24Today's Range$2.21 - $2.3652-Week Range$1.45 - $5.17Volume1.15 million shsAverage Volume818,277 shsMarket Capitalization$21.86 millionP/E RatioN/ADividend YieldN/ABeta1.59 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Fibrocell Science, Inc., an autologous cell and gene therapy company, focuses on discovering and developing therapies for diseases affecting the skin and connective tissues in the United States. The company's gene therapy product candidates include FCX-007 that is in Phase I/II clinical trials to treat recessive dystrophic epidermolysis bullosa; FCX-013, a gene therapy for localized scleroderma; and gene-therapy program that is in research phase to arthritis and related conditions. It has collaboration agreement with Intrexon Corporation for the development of FCX-007, FCX-013, and products for the treatment of chronic inflammation and degenerative diseases of human joints. The company was formerly known as Isolagen, Inc. and changed its name to Fibrocell Science, Inc. in September 2009. Fibrocell Science, Inc. was incorporated in 1992 and is based in Exton, Pennsylvania. Receive FCSC News and Ratings via Email Sign-up to receive the latest news and ratings for FCSC and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:FCSC Previous Symbol CUSIPN/A CIK357097 Webwww.fibrocell.com Phone484-713-6000Debt Debt-to-Equity RatioN/A Current Ratio6.69 Quick Ratio6.69Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$350,000.00 Price / Sales62.45 Cash FlowN/A Price / Cash FlowN/A Book Value$0.98 per share Price / Book2.29Profitability EPS (Most Recent Fiscal Year)($1.45) Net Income$-10,280,000.00 Net MarginsN/A Return on Equity-118.81% Return on Assets-64.74%Miscellaneous Employees19 Outstanding Shares9,758,000Market Cap$21.86 million Next Earnings Date5/9/2019 (Estimated) OptionableOptionable Fibrocell Science (NASDAQ:FCSC) Frequently Asked Questions What is Fibrocell Science's stock symbol? Fibrocell Science trades on the NASDAQ under the ticker symbol "FCSC." When did Fibrocell Science's stock split? How did Fibrocell Science's stock split work? Fibrocell Science shares reverse split on Friday, May 25th 2018. The 1-5 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, May 24th 2018. An investor that had 100 shares of Fibrocell Science stock prior to the reverse split would have 20 shares after the split. How were Fibrocell Science's earnings last quarter? Fibrocell Science Inc (NASDAQ:FCSC) issued its quarterly earnings results on Wednesday, March, 27th. The company reported ($0.14) earnings per share for the quarter, topping analysts' consensus estimates of ($0.62) by $0.48. View Fibrocell Science's Earnings History. When is Fibrocell Science's next earnings date? Fibrocell Science is scheduled to release their next quarterly earnings announcement on Thursday, May 9th 2019. View Earnings Estimates for Fibrocell Science. What price target have analysts set for FCSC? 2 analysts have issued 12-month price objectives for Fibrocell Science's shares. Their forecasts range from $10.00 to $22.00. On average, they anticipate Fibrocell Science's stock price to reach $16.00 in the next year. This suggests a possible upside of 614.3% from the stock's current price. View Analyst Price Targets for Fibrocell Science. What is the consensus analysts' recommendation for Fibrocell Science? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fibrocell Science in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fibrocell Science. What are Wall Street analysts saying about Fibrocell Science stock? Here are some recent quotes from research analysts about Fibrocell Science stock: 1. HC Wainwright analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and $22 price target. We point out that the large delta between the current share price and our price target is driven by the company’s relatively low share count. Further, we believe that the current share price does not reflect, despite the low patient numbers, the ability of FCX-007 to address RDEB patients’ needs, as well as the accelerated potential from a regulatory standpoint, including a Priority Review Voucher (PRV)." (3/28/2019) 2. According to Zacks Investment Research, "Fibrocell Science, Inc. is an autologous cell and gene therapy company focused on developing first-in-class treatments for rare and serious skin and connective tissue diseases with high unmet medical needs. Fibrocell's most advanced drug candidate, azficel-T, uses its FDA-approved proprietary autologous fibroblast technology and is in a Phase II clinical trial for the treatment of chronic dysphonia resulting from vocal cord scarring or atrophy. In collaboration with Intrexon Corporation, a leader in synthetic biology, Fibrocell is also developing gene therapies for orphan skin diseases using gene-modified autologous fibroblasts. The Company's lead orphan gene-therapy drug candidate, FCX-007, is in late stage pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Fibrocell is also in pre-clinical development of FCX-013, its second gene-therapy drug candidate, for the treatment of linear scleroderma. " (2/13/2019) Has Fibrocell Science been receiving favorable news coverage? News articles about FCSC stock have been trending positive on Saturday, InfoTrie reports. InfoTrie identifies positive and negative media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Fibrocell Science earned a news sentiment score of 2.6 on InfoTrie's scale. They also gave news articles about the company a news buzz of 3.0 out of 10, indicating that recent media coverage is unlikely to have an impact on the company's share price in the near term. Are investors shorting Fibrocell Science? Fibrocell Science saw a increase in short interest in March. As of March 29th, there was short interest totalling 1,432,321 shares, an increase of 40.8% from the March 15th total of 1,017,318 shares. Based on an average daily volume of 1,737,769 shares, the short-interest ratio is currently 0.8 days. Currently, 17.7% of the company's shares are short sold. View Fibrocell Science's Current Options Chain. Who are some of Fibrocell Science's key competitors? Some companies that are related to Fibrocell Science include VERONA PHARMA P/S (VRNA), Apricus Biosciences (APRI), SCYNEXIS (SCYX), Arcturus Therapeutics (ARCT), Merrimack Pharmaceuticals (MACK), Otonomy (OTIC), Eyenovia (EYEN), Elite Pharmaceuticals (ELTP), Aridis Pharmaceuticals (ARDS), Sunesis Pharmaceuticals (SNSS), Tiziana Life Sciences (TLSA), Avenue Therapeutics (ATXI), Acasti Pharma (ACST), Entasis Therapeutics (ETTX) and Medicure (MCUJF). What other stocks do shareholders of Fibrocell Science own? Based on aggregate information from My MarketBeat watchlists, some companies that other Fibrocell Science investors own include The Carlyle Group (CG), Portola Pharmaceuticals (PTLA), Celldex Therapeutics (CLDX), Inovio Pharmaceuticals (INO), Synergy Pharmaceuticals (SGYP), Verastem (VSTM), Neurotrope (NTRP), Opko Health (OPK), Sorrento Therapeutics (SRNE) and Adamis Pharmaceuticals (ADMP). Who are Fibrocell Science's key executives? Fibrocell Science's management team includes the folowing people: Mr. John Michael Maslowski, Pres, CEO & Director (Age 44)Mr. Sean D. Buckley, VP of Bus. Admin. & Corp. Sec. (Age 37)Mr. Robert G. Partridge, VP of Global Marketing, Communications and Investor RelationsMs. Michele Mchugh-Mazzatta, VP of SalesDr. Pierre Compte, Managing Director of Switzerland Who are Fibrocell Science's major shareholders? Fibrocell Science's stock is owned by many different of retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.41%). Company insiders that own Fibrocell Science stock include John Michael Maslowski and Randal J Kirk. View Institutional Ownership Trends for Fibrocell Science. Which institutional investors are buying Fibrocell Science stock? FCSC stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC. Company insiders that have bought Fibrocell Science stock in the last two years include John Michael Maslowski and Randal J Kirk. View Insider Buying and Selling for Fibrocell Science. How do I buy shares of Fibrocell Science? Shares of FCSC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Fibrocell Science's stock price today? One share of FCSC stock can currently be purchased for approximately $2.24. How big of a company is Fibrocell Science? Fibrocell Science has a market capitalization of $21.86 million and generates $350,000.00 in revenue each year. The company earns $-10,280,000.00 in net income (profit) each year or ($1.45) on an earnings per share basis. Fibrocell Science employs 19 workers across the globe. What is Fibrocell Science's official website? The official website for Fibrocell Science is http://www.fibrocell.com. How can I contact Fibrocell Science? Fibrocell Science's mailing address is 405 EAGLEVIEW BOULEVARD, EXTON PA, 19341. The company can be reached via phone at 484-713-6000 or via email at [email protected] MarketBeat Community Rating for Fibrocell Science (NASDAQ FCSC)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 216 (Vote Outperform)Underperform Votes: 210 (Vote Underperform)Total Votes: 426MarketBeat's community ratings are surveys of what our community members think about Fibrocell Science and other stocks. Vote "Outperform" if you believe FCSC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FCSC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 4/20/2019 by MarketBeat.com StaffFeatured Article: What is the downside to momentum investing?